An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia

NCT02640911 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai Mental Health Center

Phase

Observational

Started

2010-11

Last updated

2021-09-14

Condition(s) studied

Schizophrenia

Study summary

This multi-centre study will evaluate the safety and related factors study of atypical antipsychotics long-term treatment in Chinese Patients with Schizophrenia. The atypical antipsychotics include quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone, paliperidone , amisulpride , perospirone and clozapine. This is an open, cohort, multi-center observational clinical study. The main purpose is to evaluate the safety. And the second purpose is to evaluate the efficacy of atypical antipsychotics. The efficacy evaluations include symptoms, social function, recurrence rate and hospitalization. This study belongs to IV period post-marketing drugs research. Planned sample size is 3000 cases.

Visits occurs at 0,4,8,13,26,52,78,104,130 and 156 weeks. The main indexes include physical examination, vital signs, abdominal circumference , laboratory tests (blood cell analysis/ blood biochemical tests / prolactin (PRL) / thyroxine, etc.), adverse events, 12-lead electrocardiogram( ECG), extrapyramidal syndrome(EPS )assessment, sexual function evaluation, medication and other subjective feelings. The second indexes include scales of Positive and Negative Syndrome Scale(PANSS)，Clinical Global Impression-severity of Illness Scale(CGI-S), Calgary Depression Scale for Schizophrenia(CDSS),Personal and Social Performance Scale(PSP), the MOS 36一item Short Form Health Survey(SF-36), relapse rate, drug consolidation, medical-related expenses, income, drug plasma concentration and genetic information.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. An in-patient or out-patient (male or female) and aged ≥18 years 2. A diagnosis of schizophrenia,DSM-IV(Diagnostic and Statistical Manual Diploma in Social Medicine-IV) 3. Subjects must have the ability to effectively communicate with investigator,complete study related documents, comprehend the key components of the consent form and must provide written informed consent to participate in the study prior to any study specific assessments or procedures. 4. Patients are taking or will take atypical antipsychotics which include quetiapine, olanzapine, risperidone, aripiprazole, ziprasidone, paliperidone , amisulpride , perospirone and clozapine Exclusion Criteria: 1. Participation in other clinical studies. 2. Other conditions which, in the investigator's judgment, render patients unsuitable for the clinical study.

Primary outcome measure(s)

Change from Baseline Systolic Blood Pressure — at 156 weeks
Measure blood pressure at 156 weeks
Change from Baseline liver function — at 156 weeks
Measure blood biochemical tests at 156 weeks
Change from Baseline PRL — at 156 weeks
Measure PRL level at 156 weeks
Change from Baseline thyroxine — at 156 weeks
thyroxine laboratory tests at 156 weeks
Number of Participants with EPS — at 156 weeks
EPS assessment at 156 weeks
Number of Participants with abnormal ECG — at 156 weeks
ECG examination at 156 weeks
Number of participants with abnormal sexual function — at 156 weeks
sexual function evaluation medication at 156 weeks

Trial sites (1)

Facility	City	Region	Status
Shanghai Mental Health Center	Shanghai	Shanghai Municipality	Recruiting

More Shanghai Mental Health Center trials in China

The Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder Recruiting

A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders Recruiting

Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder Recruiting

Closed-loop tTIS Targeted of the Nac as an Intervention for MUD Patients Starting soon

Efficacy and Mechanism of Augmentation of Cognitive Behavioral Therapy With Transcranial Alternating Current Stimulation(tACS) for Obsessive-Compulsive Disorder (OCD) Recruiting

Other trials for the same condition

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients Recruiting

Transcranial Sonography and Machine Learning for Schizophrenia Identification Starting soon

Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia. Enrolling by invitation

Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults Starting soon

A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02640911 on ClinicalTrials.gov ↗ ← All trials in China